Validation of an automated latex particle–enhanced immunoturbidimetric von Willebrand factor activity assay

Abstract

To cite this article: Chen D, Tange JI, Meyers BJ, Pruthi RK, Nichols WL, Heit JA. Validation of an automated latex particle-enhanced immunoturbidimetric von Willebrand factor activity assay.

Von Willebrand Factor and the Right Ventricle (the MESA-Right Ventricle Study)

“…These assays do not, however, have a systematic bias and it is unlikely that vWF assay differences alone account for our results. 29 Finally, the absence of clinical cardiovascular disease in this cohort led to relatively small effect estimates. However, the difference in RV mass from the uppermost to lowermost quintiles of vWF was 3.8%, greater than the 2.8% increase in LV mass seen with diabetes in MESA.…”

Pilot investigation of a novel testing strategy for bleeding in ventricular assist device recipients

“…This finding again confirms the previous observation. 12 As an acute reactant, the elevated vWF could be related to the severity of the patient's underlying chronic disease; however, it is hard to explain why a higher vWF antigen-and collagen-binding activity is more associated with bleeding risk.…”

The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology

“…Assays based on monoclonal antibodies directed against the VWF GPIb-binding site, sometimes called ‘VWF activity assays’ have previously failed to detect type 2 VWD (Preston 1998) and although more recent versions have improved precision and sensitivity, they are not yet sufficiently reliable to replace VWF:RCo (Chen, et al 2011, Favaloro, et al 2012). Pending further data we recommend they are not relied on for diagnosis.…”